.css-1xsl8rf{width:100%;display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;-webkit-align-items:center;-webkit-box-align:center;-ms-flex-align:center;align-items:center;position:relative;overflow:hidden;background:var(--alert-bg);-webkit-padding-start:var(--chakra-space-4);padding-inline-start:var(--chakra-space-4);-webkit-padding-end:var(--chakra-space-4);padding-inline-end:var(--chakra-space-4);padding-top:var(--chakra-space-1);padding-bottom:var(--chakra-space-1);--alert-fg:var(--chakra-colors-orange-600);--alert-bg:var(--chakra-colors-orange-100);font-weight:var(--chakra-fontWeights-semibold);padding-left:var(--chakra-space-4);}.chakra-ui-dark .css-1xsl8rf:not([data-theme]),[data-theme=dark] .css-1xsl8rf:not([data-theme]),.css-1xsl8rf[data-theme=dark]{--alert-fg:var(--chakra-colors-orange-200);--alert-bg:rgba(251, 211, 141, 0.16);}@media screen and (min-width: 48em){.css-1xsl8rf{padding-left:var(--chakra-space-8);}}Bitte aktivieren Sie Javascript um alle Funktionen nutzen zu können und ihre Nutzererfahrung zu verbessern.

Ulrich Herrlinger

Bonn

Universitätsklinikum Bonn

Weitere Beteiligungen

27.10.2022
11:20 – 11:30 7 Min. 3 Min.
Abstractvortrag
Brain metastasis as first manifestation versus long-term consequence of primary cancer – does time of diagnosis matter?
27.10.2022
11:40 – 11:50 7 Min. 3 Min.
Abstractvortrag
Prognostic implications of unplanned readmission to the intensive care unit following surgery for brain metastasis
27.10.2022
11:50 – 12:00 7 Min. 3 Min.
Abstractvortrag
Survival in patients with surgically treated brain metastases: does infratentorial location matter?
27.10.2022
12:00 – 12:10 7 Min. 3 Min.
Abstractvortrag
Benchmarking of safety indicators for surgical treatment of brain metastases combined with intraoperative radiotherapy: results of a prospective observational study with comparative matched-pair analysis
27.10.2022
15:05 – 15:15 7 Min. 3 Min.
Abstractvortrag
Drug repurposing of tonabersat as a potent gap junction inhibitor sensitizes primary glioblastoma cells for temozolomide
27.10.2022
15:15 – 15:25 7 Min. 3 Min.
Abstractvortrag
Inhibition of intercellular communication via gap junctions renders medulloblastoma cells more susceptible for cytotoxic therapy
27.10.2022
15:25 – 15:35 7 Min. 3 Min.
Abstractvortrag
The Alcatraz-Strategy: A novel multimodal therapeutic approach for glioblastoma
28.10.2022
11:55 – 12:05 7 Min. 3 Min.
Abstractvortrag
Phase I/II trial of meclofenamate in progressive MGMT-methylated glioblastoma under temozolomide second-line therapy – the MecMeth/NOA-24 trial study protocol
28.10.2022
15:55 – 16:05 7 Min. 3 Min.
Abstractvortrag
Preoperative MRI shape analysis as a tool for safety profile assessment in surgery for intracranial meningioma
29.10.2022
09:10 – 09:20 7 Min. 3 Min.
Abstractvortrag
Prognostic impact of obesity in newly-diagnosed glioblastoma: A secondary analysis of CeTeG/NOA-09 and GLARIUS
29.10.2022
09:50 – 10:00 7 Min. 3 Min.
Abstractvortrag
Pathologic bone mineral density in patients with surgically treated brain metastasis from lung cancer (NSCLC): implications of an unrecognized prognostic factor
29.10.2022
10:00 – 10:10 7 Min. 3 Min.
Abstractvortrag
Low-dose acetylsalicylic acid treatment in non-skull base meningiomas: Impact on tumor proliferation and seizure burden